Literature DB >> 7814561

Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates.

A J Japour1, S A Fiscus, J M Arduino, D L Mayers, P S Reichelderfer, D R Kuritzkes.   

Abstract

A standardized assay in 96-well microtiter plates for syncytium-inducing (SI) human immunodeficiency virus type 1 phenotype detection using MT-2 cells has been developed. SI variants were found in 67% of the patients with advanced human immunodeficiency virus disease. The occurrence of the SI phenotype increased with lower CD4+ counts. There was no association between p24 antigenemia and the SI phenotype.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7814561      PMCID： PMC263986          DOI： 10.1128/jcm.32.9.2291-2294.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  17 in total

1.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

2.  Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual.

Authors:  M Groenink; R A Fouchier; R E de Goede; F de Wolf; R A Gruters; H T Cuypers; H G Huisman; M Tersmette
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

3.  Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories.

Authors:  F B Hollinger; J W Bremer; L E Myers; J W Gold; L McQuay
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

4.  HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay.

Authors:  M Koot; A H Vos; R P Keet; R E de Goede; M W Dercksen; F G Terpstra; R A Coutinho; F Miedema; M Tersmette
Journal:  AIDS       Date:  1992-01       Impact factor: 4.177

5.  A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.

Authors:  J O Kahn; S W Lagakos; D D Richman; A Cross; C Pettinelli; S H Liou; M Brown; P A Volberding; C S Crumpacker; G Beall
Journal:  N Engl J Med       Date:  1992-08-27       Impact factor: 91.245

6.  Differences in cytopathogenicity and host cell range among infectious molecular clones of human immunodeficiency virus type 1 simultaneously isolated from an individual.

Authors:  K Sakai; S Dewhurst; X Y Ma; D J Volsky
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

7.  Rapid and sensitive viral culture method for human immunodeficiency virus type 1.

Authors:  J B Jackson; R W Coombs; K Sannerud; F S Rhame; H H Balfour
Journal:  J Clin Microbiol       Date:  1988-07       Impact factor: 5.948

8.  Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture.

Authors:  H Schuitemaker; N A Kootstra; R E de Goede; F de Wolf; F Miedema; M Tersmette
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

Authors:  H Schuitemaker; M Koot; N A Kootstra; M W Dercksen; R E de Goede; R P van Steenwijk; J M Lange; J K Schattenkerk; F Miedema; M Tersmette
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

10.  A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus.

Authors:  S A Bozzette; J A McCutchan; S A Spector; B Wright; D D Richman
Journal:  J Infect Dis       Date:  1993-12       Impact factor: 5.226
View more
  27 in total

1.  Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.

Authors:  C A Derdeyn; J M Decker; J N Sfakianos; X Wu; W A O'Brien; L Ratner; J C Kappes; G M Shaw; E Hunter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism.

Authors:  Jeannette M Whitcomb; Wei Huang; Signe Fransen; Kay Limoli; Jonathan Toma; Terri Wrin; Colombe Chappey; Linda D B Kiss; Ellen E Paxinos; Christos J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

3.  Evolutionary variants of the human immunodeficiency virus type 1 V3 region characterized by using a heteroduplex tracking assay.

Authors:  J A Nelson; S A Fiscus; R Swanstrom
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.

Authors:  J R Mascola; M K Louder; T C VanCott; C V Sapan; J S Lambert; L R Muenz; B Bunow; D L Birx; M L Robb
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

5.  Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions.

Authors:  Noriaki Hosoya; Zhaohui Su; Timothy Wilkin; Roy M Gulick; Charles Flexner; Michael D Hughes; Paul R Skolnik; Françoise Giguel; Wayne L Greaves; Eoin Coakley; Daniel R Kuritzkes
Journal:  J Clin Microbiol       Date:  2009-06-03       Impact factor: 5.948

6.  Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32.

Authors:  N L Michael; J A Nelson; V N KewalRamani; G Chang; S J O'Brien; J R Mascola; B Volsky; M Louder; G C White; D R Littman; R Swanstrom; T R O'Brien
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

7.  Diversity of the envelope glycoprotein among human immunodeficiency virus type 1 isolates of clade E from Asia and Africa.

Authors:  F E McCutchan; A W Artenstein; E Sanders-Buell; M O Salminen; J K Carr; J R Mascola; X F Yu; K E Nelson; C Khamboonruang; D Schmitt; M P Kieny; J G McNeil; D S Burke
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  Longitudinal studies of viral sequence, viral phenotype, and immunologic parameters of human immunodeficiency virus type 1 infection in perinatally infected twins with discordant disease courses.

Authors:  C Hutto; Y Zhou; J He; R Geffin; M Hill; W Scott; C Wood
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

9.  Generation of representative primary virus isolates from blood plasma after isolation of HIV-1 with CD44 MicroBeads.

Authors:  Marion Cornelissen; Edwin J Heeregrave; Fokla Zorgdrager; Georgios Pollakis; William A Paxton; Antoinette C van der Kuyl
Journal:  Arch Virol       Date:  2010-09-24       Impact factor: 2.574

10.  Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism.

Authors:  Jan Weber; Ana C Vazquez; Dane Winner; Richard M Gibson; Ariel M Rhea; Justine D Rose; Doug Wylie; Kenneth Henry; Alison Wright; Kevin King; John Archer; Eva Poveda; Vicente Soriano; David L Robertson; Paul D Olivo; Eric J Arts; Miguel E Quiñones-Mateu
Journal:  J Clin Microbiol       Date:  2013-03-13       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.